TNF and glycogen storage disease VI: In the CD patients with colonic/ileocolonic disease from GSE52746, patients had been treated with two types of TNFα inhibitors (subcutaneous adalimumab of intravenous infliximab) and matched samples before and after treatment were only available for six adalimumab-treated patients, of which 5 responder and one non-responder patient; thus statistical analysis was not possible (Supplementary Figure S3).